Toll Free: 1-888-202-9519

Valneva SE - Product Pipeline Review - 2015

Oct 21, 2015 | 35 Pages | Global Markets Direct | Pharmaceuticals & Healthcare

Valneva SE - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Valneva SE - Product Pipeline Review - 2015', provides an overview of the Valneva SE's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Valneva SE's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Valneva SE including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Valneva SE's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Valneva SE's pipeline products

Reasons to Buy

- Evaluate Valneva SE's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Valneva SE in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Valneva SE's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Valneva SE and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Valneva SE
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Valneva SE and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents
2 List of Tables 4 List of Figures 4 Valneva SE Snapshot 5 Valneva SE Overview 5 Key Information 5 Key Facts 5 Valneva SE - Research and Development Overview 6 Key Therapeutic Areas 6 Valneva SE - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Valneva SE - Pipeline Products Glance 14 Valneva SE - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Valneva SE - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Valneva SE - Drug Profiles 17 VLA-43 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Vaccine for Undisclosed Indication 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 VLA-84 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 VLA-15 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Antibodies for Pneumococcus Infections 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Valneva SE - Pipeline Analysis 23 Valneva SE - Pipeline Products by Target 23 Valneva SE - Pipeline Products by Route of Administration 24 Valneva SE - Pipeline Products by Molecule Type 25 Valneva SE - Recent Pipeline Updates 26 Valneva SE - Dormant Projects 30 Valneva SE - Discontinued Pipeline Products 31 Discontinued Pipeline Product Profiles 31 IC-41 31 IC-47 31 VLS-732 31 VLS-801 31 Valneva SE - Locations And Subsidiaries 32 Head Office 32 Other Locations & Subsidiaries 32 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 34 Disclaimer 35
List of Tables
Valneva SE, Key Information 5 Valneva SE, Key Facts 5 Valneva SE - Pipeline by Indication, 2015 7 Valneva SE - Pipeline by Stage of Development, 2015 8 Valneva SE - Monotherapy Products in Pipeline, 2015 9 Valneva SE - Partnered Products in Pipeline, 2015 10 Valneva SE - Partnered Products/ Combination Treatment Modalities, 2015 11 Valneva SE - Out-Licensed Products in Pipeline, 2015 12 Valneva SE - Out-Licensed Products/ Combination Treatment Modalities, 2015 13 Valneva SE - Phase II, 2015 14 Valneva SE - Preclinical, 2015 15 Valneva SE - Discovery, 2015 16 Valneva SE - Pipeline by Target, 2015 23 Valneva SE - Pipeline by Route of Administration, 2015 24 Valneva SE - Pipeline by Molecule Type, 2015 25 Valneva SE - Recent Pipeline Updates, 2015 26 Valneva SE - Dormant Developmental Projects,2015 30 Valneva SE - Discontinued Pipeline Products, 2015 31 Valneva SE, Subsidiaries 32


List of Figures
Valneva SE - Pipeline by Top 10 Indication, 2015 7 Valneva SE - Pipeline by Stage of Development, 2015 8 Valneva SE - Monotherapy Products in Pipeline, 2015 9 Valneva SE - Partnered Products in Pipeline, 2015 10 Valneva SE - Pipeline by Top 10 Target, 2015 23 Valneva SE - Pipeline by Top 10 Molecule Type, 2015 25

To request a sample copy of this report, please complete the form below.

Please Fill captcha Validation: 3bkQ3w
This website is secure and your personal details are safe. Privacy policy

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...October 8, 2015

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...October 6, 2015

Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected to

Read More...October 6, 2015

Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over t

Read More...November 18, 2015

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...October 6, 2015
Choose License Type
Single User - US$ 1500.00
Multi User - US$ 3000.00
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify
Latest Publication